Alvotech
ALVOW
NASDAQ Global Market0.19
USD
+0.01
- -
CIK
0001898416
ISIN
LU2458333858
CUSIP
L01800116
Return %
Stock
S&P500
1Y
-89.42
18.99
3Y
-87.82
64.75
5Y
-85.54
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Lisa Graver
- Full Time Employees
- 1,279
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 9, Rue de Bitbourg Luxembourg LU Luxembourg L-1273
- IPO Date
- Jun 16, 2022
- CIK
- 0001898416
- Website
- alvotech.com
- Similar Companies
- Business
- Alvotech Alvotech (NASDAQ:ALVOW), founded in 2013 and headquartered in Reykjavik, Iceland, is a biotechnology company that develops and manufactures biosimilar medicines through its subsidiaries to expand global access to affordable biologic treatments. The company employs a vertically integrated approach encompassing cell line development, process development, clinical trials, and commercial-scale manufacturing at facilities in Iceland, Germany, Sweden, Switzerland, and India; it operates across Europe, North America, Asia-Pacific, Latin America, the Middle East, and Africa via strategic commercial partnerships. Its pipeline features biosimilar candidates targeting immunology (adalimumab/AVT02 to HUMIRA, ustekinumab/AVT04 to STELARA, golimumab/AVT05 to SIMPONI, vedolizumab/AVT16 to ENTYVIO, certolizumab pegol/AVT10 to CIMZIA, ixekizumab/AVT28 to TALTZ, canakinumab/AVT48 to ILARIS, guselkumab/AVT41 to TREMFYA, ofatumumab/AVT65 to KESIMPTA, dupilumab/AVT19 to DUPIXENT), bone disease (denosumab/AVT03 to PROLIA/XGEVA), ophthalmology (aflibercept/AVT06 to EYLEA), respiratory disease (omalizumab/AVT23 to XOLAIR), and oncology (pembrolizumab/AVT33 to KEYTRUDA), with several candidates approved in regions including the US, Europe/EEA, Japan, Canada, Australia, and others. Recent developments include European Economic Area approval for AVT03 (denosumab biosimilar) and Gobivaz (AVT05 golimumab biosimilar, first-in-market to SIMPONI via Advanz Pharma partnership); expansion of the Advanz Pharma alliance in May 2025 to commercialize three additional candidates (including biosimilars to Ilaris and Kesimpta) for up to $180 million in milestones plus revenue share, targeting over ten reference products in Europe from 2025 through 2030; a June 2025 collaboration with Dr. Reddy's Laboratories to co-develop, manufacture, and commercialize a pembrolizumab (Keytruda) biosimilar globally; and completion of the Xbrane Biopharma R&D acquisition in early June 2025, incorporating approximately 40 employees, operations in Stockholm, Sweden, and a certolizumab pegol (Cimzia) biosimilar candidate for roughly $28.9 million.
Alvotech (ALVO) Q1 2026 Earnings Call Transcript
Alvotech (NASDAQ:ALVOW) Sees Significant Decrease in Short Interest
Short Interest in Alvotech (NASDAQ:ALVOW) Increases By 32.7%
Alvotech (NASDAQ:ALVOW) Stock Price Down 20.3% – Here’s What Happened
Alvotech (NASDAQ:ALVOW) Stock Price Up 1.4% – Still a Buy?